The disposition of clavulanic acid in man

Xenobiotica; the Fate of Foreign Compounds in Biological Systems
G C BoltonD J Jeffery

Abstract

Following oral administration of potassium 14C-clavulanate to four human subjects, at least 73% of the radioactive dose was absorbed. The mean absolute bioavailability was 64%. Absorption was rapid with peak plasma concentrations of radioactivity and clavulanic acid (2-6 micrograms/ml) occurring between 45 min and three hours after dosing. Values for the volume of distribution at steady-state and terminal half-life of clavulanic acid in the plasma were 12.01 and 0.8 h respectively. Following intravenous administration of clavulanic acid to the same subjects, the clearance, and volume of distribution at steady-state were 0.21 l/min, and 12.01, respectively. Clavulanic acid was the major radioactive component present in 0-24 h urine following oral dosing (23% of the dose). The two major metabolites were 2,5-dihydro-4-(2-hydroxyethyl)-5-oxo-1H-pyrrole-3-carboxylic acid (15% of the dose) and 1-amino-4-hydroxybutan-2-one (8.8% of the dose). Clavulanic acid and 1-amino-4-hydroxybutan-2-one were the major components in plasma following oral administration (52 and 21% of plasma radioactivity respectively at two hours after dosing). The major route of excretion of radioactivity following oral administration was via the urine (73% of the...Continue Reading

References

Jun 1, 1978·The Journal of Antibiotics·S W Elson, R S Oliver
May 1, 1977·Antimicrobial Agents and Chemotherapy·C Reading, M Cole
Jun 1, 1976·The Journal of Antibiotics·A G BrownG N Rolinson
Aug 1, 1976·Journal of Pharmaceutical Sciences·P R Byron, R E Notari
Sep 1, 1971·Analytical Biochemistry·W A ShawA Bennett
Jun 1, 1984·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·G C BoltonD J Jeffery
Jan 1, 1983·Chemical & Pharmaceutical Bulletin·K TagawaS Goto
Oct 1, 1980·Journal of Pharmacokinetics and Biopharmaceutics·S Riegelman, P Collier
Jan 1, 1985·Journal of Pharmaceutical and Biomedical Analysis·B LeggG A Wadds

❮ Previous
Next ❯

Citations

Aug 1, 1997·Natural Product Reports·K H BaggaleyC J Schofield
Oct 20, 2005·Clinical Pharmacokinetics·Amparo Sánchez Navarro
Aug 9, 2011·Annual Review of Pharmacology and Toxicology·Ann K Daly
Feb 1, 2012·Expert Opinion on Drug Metabolism & Toxicology·David E Amacher
Sep 25, 2007·Chemistry & Biodiversity·Bernard Testa, Stefanie D Krämer
Oct 27, 1999·Gastroenterology·M L HautekeeteA P Geubel
Dec 28, 2018·Pharmacotherapy·Ryan L Crass, Manjunath P Pai
May 21, 2003·Journal of Veterinary Pharmacology and Therapeutics·T B VreeE Van Duuren
Nov 1, 1989·The Journal of International Medical Research·J P DesagerC Harvengt

❮ Previous
Next ❯

Related Concepts

Related Feeds

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

© 2021 Meta ULC. All rights reserved